Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (canceled)

2. (currently amended): The recombinant avian herpesvirus of claim ~~1~~ 50 wherein the foreign DNA sequence is selected from the group consisting of [[:]] a Newcastle disease virus fusion gene, an infectious laryngotracheitis virus glycoprotein D gene, [[or]] and an infectious laryngotracheitis glycoprotein I gene.

3. (original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the Newcastle disease virus fusion gene.

4. (currently amended): The recombinant avian herpesvirus of claim 3 ~~designated~~ comprised by NAHV/NDV 295-93 (ATCC Accession number PTA-3453).

5. (original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein D gene.

6. (original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein I gene.

7. (curently amended): The recombinant avian herpesvirus of claim ~~2~~ 50 wherein the foreign DNA sequences are the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene.

8. (currently amended): The recombinant avian herpesvirus of claim 7 ~~designated~~ comprised by NAHV/ILT 295-149 (ATCC Accession number PTA-3452).

9. (currently amended): The recombinant avian herpesvirus of claim ~~2~~ 50 wherein the foreign DNA sequences are the Newcastle disease virus fusion gene, the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene.

10. (currently amended): The recombinant avian herpesvirus ~~designated~~ comprised by NAHV 295-01 (ATCC Accession number PTA-3451).

11. (original): A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 3 and a suitable carrier.

12. (original): A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 4 and a suitable carrier.

13. (original): A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 7 and a suitable carrier.

14. (original): A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 8 and a suitable carrier.

15. (previously presented): A vaccine for protecting against Marek's disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 10 and a suitable carrier.

16. (original): A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 9 and a suitable carrier.

17. (currently amended): A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising, as a mixture, an effective immunizing amount of a first recombinant avian herpesvirus, ~~designated~~ comprised by NAHV/ILT 295-149 (ATCC Accession number PTA-3452), an effective immunizing amount of a second recombinant avian herpesvirus, ~~designated~~ comprised by NAHV/NDV 295-93 (ATCC Accession number PTA-3453), and a suitable carrier.

18. (original): A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 11.

19. (original): A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 12.

20. (original): A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of claim 13.

21. (original): A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of claim 14.

22. (previously presented): A method of immunizing an avian species against Marek's disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 15.

23. (original): A method of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 16.

24. (original): The vaccine as in claim 11 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

25. (original): The vaccine as in claim 13 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

26. (original): The vaccine as in claim 15 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

27. (original): The vaccine as in claim 16 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

28. (original): The method of claim 18, wherein the vaccine is administered by injection.

29. (original): The method of claim 20, wherein the vaccine is administered by injection.

30. (original): The method of claim 22, wherein the vaccine is administered by injection.

31. (original): The method of claim 23, wherein the vaccine is administered by injection.

32. (original): The method of claim 18, wherein the vaccine is administered intraocularly.

33. (original): The method of claim 20, wherein the vaccine is administered intraocularly.

34. (original): The method of claim 22, wherein the vaccine is administered intraocularly.

35. (original): The method of claim 23, wherein the vaccine is administered intraocularly.

36. (original): The method of claim 18, wherein the vaccine is administered orally.

37. (original): The method of claim 20, wherein the vaccine is administered orally.

38. (original): The method of claim 22, wherein the vaccine is administered orally.

39. (original): The method of claim 23, wherein the vaccine is administered orally.

40-41: (canceled)

42. (currently amended): A vaccine for protecting against Marek's disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim [[41]] 48 and a suitable carrier.

43. (previously presented): A method of immunizing an avian species against Marek's disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 42.

44. (previously presented): The vaccine as in claim 42 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

45. (previously presented): The method of claim 43, wherein the vaccine is administered by injection.

46. (previously presented): The method of claim 43, wherein the vaccine is administered intraocularly.

47. (previously presented): The method of claim 43, wherein the vaccine is administered orally.

48. (new): A recombinant avian herpesvirus comprising a Marek's disease virus (MDV) unique short viral genome region, a herpesvirus of turkeys (HVT) unique long viral genome region, and the repeat viral genome regions of the HVT; wherein the recombinant avian herpesvirus is capable of being expressed in a host cell.

49. (new): The recombinant avian herpesvirus of Claim 48 further comprising at least one foreign DNA sequence inserted into a nonessential site of the recombinant avian herpesvirus.

50. (new): The recombinant avian herpesvirus of Claim 49 wherein the MDV unique short region comprises a US2 gene into which the at least one foreign DNA sequence is inserted.

51. (new): A vaccine for protecting against Marek's disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 10 and a suitable carrier.

52. (new): A method of immunizing an avian species against Marek's disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 51.